A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Samyang Group
- 02 May 2017 Status changed from recruiting to completed.
- 28 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Apr 2010 New trial record